TY - JOUR
T1 - Cardiovascular Biomarkers and Imaging in Older Adults
T2 - JACC Council Perspectives
AU - Geriatric Cardiology Section Leadership Council
AU - Forman, Daniel E.
AU - de Lemos, James A.
AU - Shaw, Leslee J.
AU - Reuben, David B.
AU - Lyubarova, Radmila
AU - Peterson, Eric D.
AU - Spertus, John A.
AU - Zieman, Susan
AU - Salive, Marcel E.
AU - Rich, Michael W.
N1 - Funding Information:
The authors acknowledge Deborah Berlyne, PhD, medical writer, for her work in transcribing and synthesizing the meeting materials. This Council Perspective was funded by the National Institute on Aging through grant U13AG047008, with additional funding from Edwards Lifesciences and Pfizer, Inc. Dr. Forman received funds from the National Institute of Aging and the National Institute of Health Common fund through grants R01AG060499, R01AG058883, P30AG024827, and UO1AR071130. Dr. de Lemos has received grant support from Roche Diagnostics and Abbott Diagnostics; has received consulting income from Roche Diagnostics, Abbott Diagnostics, Ortho Clinical Diagnostics, and Quidel Cardiovascular; and is the co-inventor on a patent to University of Maryland: 15/309,754 “Methods for Assessing Differential Risk for Developing Heart Failure.” Dr. Petersen has received research support and consulting income from Amgen, AstraZeneca, Janssen, Sanofi, and Merck. Dr. Spertus owns the copyright to the Seattle Angina Questionnaire (SAQ), Kansas City Cardiomyopathy Questionnaire (KCCQ), and Peripheral Artery Questionnaire (PAQ). Dr. Rich has received funds from the National Institute of Aging through grant R01AG060499. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Funding Information:
This Council Perspective was funded by the National Institute on Aging through grant U13AG047008, with additional funding from Edwards Lifesciences and Pfizer, Inc. Dr. Forman received funds from the National Institute of Aging and the National Institute of Health Common fund through grants R01AG060499, R01AG058883, P30AG024827, and UO1AR071130. Dr. de Lemos has received grant support from Roche Diagnostics and Abbott Diagnostics; has received consulting income from Roche Diagnostics, Abbott Diagnostics, Ortho Clinical Diagnostics, and Quidel Cardiovascular; and is the co-inventor on a patent to University of Maryland: 15/309,754 “Methods for Assessing Differential Risk for Developing Heart Failure.” Dr. Petersen has received research support and consulting income from Amgen, AstraZeneca, Janssen, Sanofi, and Merck. Dr. Spertus owns the copyright to the Seattle Angina Questionnaire (SAQ), Kansas City Cardiomyopathy Questionnaire (KCCQ), and Peripheral Artery Questionnaire (PAQ). Dr. Rich has received funds from the National Institute of Aging through grant R01AG060499. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2020 American College of Cardiology Foundation
PY - 2020/9/29
Y1 - 2020/9/29
N2 - Whereas the burgeoning population of older adults is intrinsically vulnerable to cardiovascular disease, the utility of many management precepts that were validated in younger adults is often unclear. Whereas biomarker- and imaging-based tests are a major part of cardiovascular disease care, basic assumptions about their use and efficacy cannot be simply extrapolated to many older adults. Biology, physiology, and body composition change with aging, with important influences on cardiovascular disease testing procedures and their interpretation. Furthermore, clinical priorities of older adults are more heterogeneous, potentially undercutting the utility of testing data that are collected. The American College of Cardiology and the National Institutes on Aging, in collaboration with the American Geriatrics Society, convened, at the American College of Cardiology Heart House, a 2-day multidisciplinary workshop, “Diagnostic Testing in Older Adults with Cardiovascular Disease,” to address these issues. This review summarizes key concepts, clinical limitations, and important opportunities for research.
AB - Whereas the burgeoning population of older adults is intrinsically vulnerable to cardiovascular disease, the utility of many management precepts that were validated in younger adults is often unclear. Whereas biomarker- and imaging-based tests are a major part of cardiovascular disease care, basic assumptions about their use and efficacy cannot be simply extrapolated to many older adults. Biology, physiology, and body composition change with aging, with important influences on cardiovascular disease testing procedures and their interpretation. Furthermore, clinical priorities of older adults are more heterogeneous, potentially undercutting the utility of testing data that are collected. The American College of Cardiology and the National Institutes on Aging, in collaboration with the American Geriatrics Society, convened, at the American College of Cardiology Heart House, a 2-day multidisciplinary workshop, “Diagnostic Testing in Older Adults with Cardiovascular Disease,” to address these issues. This review summarizes key concepts, clinical limitations, and important opportunities for research.
KW - aging
KW - biomarkers
KW - cardiovascular testing
KW - imaging
KW - shared decision making
KW - stress testing
UR - http://www.scopus.com/inward/record.url?scp=85090826776&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2020.07.055
DO - 10.1016/j.jacc.2020.07.055
M3 - Review article
C2 - 32972536
AN - SCOPUS:85090826776
SN - 0735-1097
VL - 76
SP - 1577
EP - 1594
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 13
ER -